Is Novartis AG a good investment? Novartis AG (0QLR.IL) is currently trading at 117.61 CHF.
In terms of valuation, the stock trades at a P/E ratio of 36.56. This high multiple suggests investors have priced in significant future growth expectations.
For income investors, Novartis AG pays a dividend yield of 3.78%. With a payout ratio of 97%, the dividend appears to be under pressure.
Yes, it pays an annual dividend of 3.20 CHF (3.78% yield).
Novartis AG is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
3.78%
3.20 CHF
March 10, 2026
97.31%
| Year | Total Dividends |
|---|---|
| 2027 | 3.81 CHF |
| March 2, 2027 (estimated) | 3.8053 |
| 2026 | 3.70 CHF |
| March 10, 2026 | 3.7000 |
| 2025 | 3.50 CHF |
| March 11, 2025 | 3.5000 |
| 2024 | 3.30 CHF |
| March 7, 2024 | 3.3000 |
| 2023 | 3.20 CHF |
| March 9, 2023 | 3.2000 |
| 2022 | 3.10 CHF |
| March 8, 2022 | 3.1000 |
| 2021 | 3.00 CHF |
| March 4, 2021 | 3.0000 |
| 2020 | 2.95 CHF |
| March 3, 2020 | 2.9500 |
| 2018 | 2.80 CHF |
| March 6, 2018 | 2.8000 |
| 2017 | 2.75 CHF |
| March 2, 2017 | 2.7500 |
Yearly aggregated dividends
|
Novartis AG
Mar 10, 2026 Paid
Dividend
3.7 CHF |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 4, 2023 | 1.200000 |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion